Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Biosimilars, Business Practice, Trends & Forecasts

Breaking Barriers to Biosimilars

Sitting Down With… Richard Markus, Vice President of Global Development, Amgen, USA.

James Strachan |

How did you get your start in pharma?

I’ve always been interested in science, especially biology, but my first job after college actually involved statistical programming in the pharma industry. As I learned more about the industry, my interest in it – and particularly in clinical research – grew. So my next step was to go back to school and earn my MD and PhD, with the expectation of going back to the field of drug development as a physician. I started working at Amgen around 11 years ago as a physician scientist. I worked with a fantastic team to develop a bone-targeting agent (XGEVA; denosumab) for cancer patients, which was in phase II trials at the time. It was a very large effort involving multiple studies in patients with different cancers, so it was an exciting way to start my career.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Login

Forgot your password?

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

Business & Regulation Biosimilars, Business Practice, Trends & Forecasts

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Related Webinars

Business & Regulation Advanced Medicine

FDA Accelerated Approval Pathways for Cell and Gene Therapy products

| Sponsored by Thermo Fisher Scientific

Business & Regulation Advanced Medicine

Cell Therapy Facilities – Designing for Flexibility, Scalability, and Cost Effectiveness

| Sponsored by CRB

Business & Regulation Facilities

Maintaining a Fit Facility: Stress Testing, Mitigating Risks and Remediation

| Sponsored by CRB

Most Popular

1. Business & Regulation Business Practice

Crafting a Culture of Excellence

| Maryam Mahdi

2. Business & Regulation Business Practice

Stemming the Brain Drain

| Kelly Chibale

3. Business & Regulation Business Practice

Building a Beautiful Biotech

| James Strachan

4. Manufacture Formulation

The Rise of Lipid Nanoparticles

| Rahul Keswani, Benjamin King

5. Discovery & Development Drug Delivery

Melt in the Mouth

| Elizabeth Hickman

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

December Issue of The Medicine Maker